Celgene Profile

Performance

1919

Odds of Distress

Analyze Filter    Fiscal Quarter End: December 31, 2019
Equity ratings for Celgene Corporation are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting September 13, 2019 and ending today December 12, 2019. Click here to learn more.

Celgene Profile

Next fiscal quarter end is expected on December 31, 2019. Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey. Celgene operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 8852 people. more
NameCelgene Corporation
CEOPerry KarsenView All
Thematic Classifications
Active Investing Ideas
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Bond Rating
BBB+Good
Specialization
Healthcare, Pharmaceuticals And Biosciences
InstrumentUSA Stock View All
RegionNorth America
Business Address86 Morris Avenue, Summit, NJ 07901, United States
ExchangeBATS Exchange
CIK Number0000816284
ISINUS1510201049
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.celgene.com
Phone908 673 9000
CurrencyUSD - US Dollar
Celgene Corporation (CELG) is traded on BATS Exchange in USA and employs 8,852 people. The company currently falls under 'Large-Cap' category with current market capitalization of 77.04 B. Celgene conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 708.74 M outstanding shares of which 12.95 M shares are currently shorted by private and institutional investors with about 3.45 trading days to cover. CELGENE CP currently holds about 9.32 B in cash with 6.35 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.15.
Check Celgene Probability Of Bankruptcy

Ownership Allocation (%)

Celgene Target Price Odds Analysis

Odds Below 108.24HorizonTargetOdds Above 108.24
83.11%30 days 108.24 16.72%
Based on normal probability distribution, the odds of Celgene to move above current price in 30 days from now is about 16.72 (This Celgene Corporation probability density function shows the probability of Celgene Stock to fall within a particular range of prices over 30 days) .

Celgene Top Holders

Celgene Corporation Income Statement Over Time

Direct Expenses    Earning Before Interest and Taxes EBIT    Net Income    

Celgene Key Fundamentals

Celgene Against Markets

Did you try this?

Run Alpha Finder Now

   

Alpha Finder

Use alpha and beta coefficients to find investment opportunities after accounting for the risk
All  Next Launch Module

Celgene Upcoming and Recent Events

Celgene Company Earnings Announcements Dates

Upcoming Quarterly Earning ReportJanuary 30, 2020
Next Earnings ReportApril 23, 2020
Next Fiscal Quarter EndDecember 31, 2019
Next Fiscal Year EndJanuary 30, 2020
Last Quarter Report DateSeptember 30, 2019
Last Earning Anouncement DateDecember 31, 2018

Celgene Corporate Filings

Celgene SEC Reporting

Financial Statements and Exhibits. Material Modifications to Rights of Security Holders. Completion of Acquisition or Disposition of Assets
Unclassified Corporate Event. Unclassified Corporate Event. Unclassified Corporate Event. Unclassified Corporate Event. Completion of Acquisition or Disposition of Assets
Other Events
Regulation FD Disclosure

Celgene Corporate Directors

James Loughlin Independent Director
Michael Friedman Independent Director
Michael Bonney Director
Check also Trending Equities. Please also try Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Search macroaxis.com